ACXP:NASDAQ, Acurx Pharmaceuticals, Inc.
ACXP stock overview
Acurx Pharmaceuticals, Inc. (ACXP:NASDAQ) closed at $1.02 on November 3, 2026,
down 4.67% on the day.
The stock trades 86.5% below its 52-week high of $7.54
and 1.0% above its 52-week low of $1.01.
Over the past year, it lost 77.8%.
Acurx Pharmaceuticals, Inc. is part of the Health Care sector.
Key figures
- Price
- $1.02
- Day change
- -4.67%
- Volume
- 203,839
- Average volume
- 118,926
- Market cap
- 5M+
- 52-week range
- $1.01 – $7.54
- 50-day average
- $1.29
- 200-day average
- $1.97
Price action over the past year
In 252 trading sessions since November 3, 2025, ACXP closed higher on 88 days (35%).
Its best day was March 11, 2026 (+107.93%) and its worst was March 13, 2026 (-22.55%).
The stock moved 10% or more in a single session 23 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
ACXP news
-
Oct 31, 2026:
From Global Private Credit to Programmable Securities: New to The Street Show #778 Premieres Tonight on Bloomberg Television
-
Oct 26, 2026:
Acurx Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 12, 2026 Conference Call and Provide Business Update
-
Oct 24, 2026:
From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television
-
Oct 21, 2026:
Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect
-
Oct 5, 2026:
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
-
Sep 29, 2026:
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
-
Sep 19, 2026:
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
-
Sep 14, 2026:
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
Similar stocks
Find more stocks like ACXP with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.